Table 2.

Clinical evidence for tailoring DAPT based on platelet function testing.

	Study Population	Treatment Strategy	Primary End Point	Result
GRAVITAS trial (2011) [18]	Post PCI patient with drug eluting stent	After platelet function testing patients were given high-dose (150 mg daily) or standard-dose clopidogrel (75 mg daily)	Cardiovascular death, nonfatal MI or stent thrombosis at 6 months	In patients with high on-treatment reactivity after PCI with drug eluting stents, the use of high dose clopidogrel compared with standard dose clopidogrel did not reduce primary outcome
ARCTIC-GENE study (2015) [19]	Stable angina/NSTE-ACS undergoing PCI with DES implantation	Platelet function analysis in post PCI patients and clopidogrel dose adjustment	Composite of death, MI, stent thrombosis, stroke, or urgent revascularization at 12 months	No significant difference between two groups
TAILOR PCI (2020) [20]	Patients undergoing PCI for ACS or CCS	Genotype guided P2Y12 inhibitor verses conventional (no genotyping, clopidogrel in all)	Composite of cardiovascular death, myocardial infarction, stroke, stent thrombosis, and severe recurrent ischemia at 12 months	No significant difference between two groups